These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 22130111)

  • 1. Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS).
    Grimaldi-Bensouda L; Rouillon F; Astruc B; Rossignol M; Benichou J; Falissard B; Limosin F; Beaufils B; Vaiva G; Verdoux H; Moride Y; Fabre A; Thibaut F; Abenhaim L;
    Schizophr Res; 2012 Feb; 134(2-3):187-94. PubMed ID: 22130111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences in treatment effect among clinical subgroups in a randomized clinical trial of long-acting injectable risperidone and oral antipsychotics in unstable chronic schizophrenia.
    Leatherman SM; Liang MH; Krystal JH; Lew RA; Valley D; Thwin SS; Rosenheck RA;
    J Nerv Ment Dis; 2014 Jan; 202(1):13-7. PubMed ID: 24375206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness of risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort study.
    Nielsen J; Jensen SO; Friis RB; Valentin JB; Correll CU
    Schizophr Bull; 2015 May; 41(3):627-36. PubMed ID: 25180312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: implications for dopamine D2 receptor occupancy during maintenance treatment in schizophrenia.
    Ikai S; Remington G; Suzuki T; Takeuchi H; Tsuboi T; Den R; Hirano J; Tsunoda K; Nishimoto M; Watanabe K; Mimura M; Mamo D; Uchida H
    J Clin Psychiatry; 2012 Aug; 73(8):1147-52. PubMed ID: 22967779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "Impact of drug-reimbursement policies on prescribing: A case-study of a newly marketed long-acting injectable antipsychotic among relapsed schizophrenia patients".
    Jackson JW; Fulchino L; Rogers J; Mogun H; Polinski J; Henderson DC; Schneeweiss S; Fischer MA
    Pharmacoepidemiol Drug Saf; 2018 Jan; 27(1):95-104. PubMed ID: 29168261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hospitalization resource utilization and costs among Medicaid insured patients with schizophrenia with different treatment durations of long-acting injectable antipsychotic therapy.
    Bera R; Offord S; Zubek D; Lau G; Lin J; Karson C
    J Clin Psychopharmacol; 2014 Feb; 34(1):30-5. PubMed ID: 24135840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment discontinuation of long-acting injectables or oral atypical antipsychotics among Medicaid recipients with schizophrenia.
    Song X; El Khoury AC; Brouillette M; Smith D; Joshi K
    J Med Econ; 2019 Nov; 22(11):1105-1112. PubMed ID: 31062998
    [No Abstract]   [Full Text] [Related]  

  • 8. Concurrent Oral Antipsychotic Drug Use Among Schizophrenia Patients Initiated on Long-Acting Injectable Antipsychotics Post-Hospital Discharge.
    Doshi JA; Pettit AR; Stoddard JJ; Zummo J; Marcus SC
    J Clin Psychopharmacol; 2015 Aug; 35(4):442-6. PubMed ID: 26075492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of initiating long-acting injectable antipsychotics on hospitalization in patients with bipolar I disorder.
    Yan T; Greene M; Chang E; Touya M; Broder MS
    J Comp Eff Res; 2018 Nov; 7(11):1083-1093. PubMed ID: 30129771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.
    Li H; Rui Q; Ning X; Xu H; Gu N
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1002-8. PubMed ID: 21315787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Subjective Experiences and Effectiveness of First-Generation Long-Acting Injectable Antipsychotics and Risperidone Long-Acting Injectables in Patients With Schizophrenia.
    Chen WY; Lin SK
    J Clin Psychopharmacol; 2016 Oct; 36(5):492-5. PubMed ID: 27580495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Long acting injectable antipsychotics in the treatment of schizophrenia: a review of literature].
    Graffino M; Montemagni C; Mingrone C; Rocca P
    Riv Psichiatr; 2014; 49(3):115-23. PubMed ID: 25000887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study.
    Barrio P; Batalla A; Castellví P; Hidalgo D; García M; Ortiz A; Grande I; Pons A; Parellada E
    Int Clin Psychopharmacol; 2013 Jul; 28(4):164-70. PubMed ID: 23587986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic review of long-acting injectables versus oral atypical antipsychotics on hospitalization in schizophrenia.
    Lafeuille MH; Dean J; Carter V; Duh MS; Fastenau J; Dirani R; Lefebvre P
    Curr Med Res Opin; 2014 Aug; 30(8):1643-55. PubMed ID: 24730586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of long-acting injectable risperidone before and throughout pregnancy in schizophrenia.
    Kim SW; Kim KM; Kim JM; Shin IS; Shin HY; Yang SJ; Yoon JS
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):543-5. PubMed ID: 17110011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between second-generation antipsychotic medication half-life and hospitalization in the community treatment of adult schizophrenia.
    Broder MS; Bates JA; Jing Y; Hebden T; Forbes RA; Chang E
    J Med Econ; 2012; 15(1):105-11. PubMed ID: 21991926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-acting injectable vs oral risperidone for schizophrenia and co-occurring alcohol use disorder: a randomized trial.
    Green AI; Brunette MF; Dawson R; Buckley P; Wallace AE; Hafez H; Herz M; Narasimhan M; Noordsy DL; O'Keefe C; Sommi RW; Steinbook RM; Weeks M
    J Clin Psychiatry; 2015 Oct; 76(10):1359-65. PubMed ID: 26302441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of an Institutional Medication Adherence Program for Long-Acting Injectable Risperidone on Adherence and Psychiatric Hospitalizations: Evidence from a Prospective Cohort Study.
    Jalbert JJ; Rossignol M; Astruc B; Baylé F; Nordon C; Avouac B; Rouillon F; Abenhaim L; Grimaldi-Bensouda L
    J Popul Ther Clin Pharmacol; 2017 May; 24(2):e61-e70. PubMed ID: 28594483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
    Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
    Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health service utilization and medical costs among patients with schizophrenia receiving long-acting injectable risperidone versus oral risperidone: a nationwide retrospective matched cohort study in Taiwan.
    Fan SJ; Lu N; Chang HC; Tang CH; Huang KC
    Int Clin Psychopharmacol; 2018 Jul; 33(4):204-212. PubMed ID: 29489495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.